medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Number 2

<< Back Next >>

Ann Hepatol 2006; 5 (2)

Metabolic syndrome, non-alcoholic steatohepatitis (NASH), and hepatocyte growth factor (HGF)

Balaban YH, Sumer H, Simsek H, Us D, Tatar G

Language: English
References: 31
Page: 109-114
PDF size: 89.30 Kb.


Text Extraction

Background: Hepatocyte growth factor (HGF) is not only an antiapoptotic and antifibrotic factor of liver, but it is also an adipokine. Serum HGF levels are strongly associated with liver diseases, obesity, insulin resistance (IR), and metabolic syndrome (MS). Non-alcoholic steatohepatitis (NASH) is the hepatic component of MS. To the best of our knowledge, serum HGF levels in patients with NASH have not been previously studied. Our aim was to elucidate the correlation of HGF with the clinical and histopathological parameters of NASH. Methods: The study group consisted of 26 patients (13 men) who had clinical diagnoses of NASH and underwent liver biopsies. Controls were 13 volunteers (3 men) with negative viral autoimmune markers, and with normal levels of serum lipids and liver enzymes. Results: Among the NASH patients, 14 (54%) were overweight and 10 (39%) had grade I-II obesity. All the patients had class 3-4 non-alcoholic fatty liver disease (NAFLD) except for 2 who had class 2 disease. All of the patients had Child’s class A liver disease, and MS was present in 5 (19%) patients and 8 (31%) patients had Homeostasis Model Assessment of Insulin Resistance (HOMA) › 3. Serum HGF levels were similar in NASH patients (1.24 ± 1.09 pg/mL) and controls (0.86 ± 0.22 pg/mL) (p = 0.21). The levels of serum HGF did not differ between the patients with or without MS (1.65 ± 1.48 pg/mL and 1.04 ± 0.80 pg/mL, respectively, p=0.65). HGF was not correlated with the laboratory or histopathological parameters. Conclusions: Serum HGF levels were higher in NASH patients than in the controls, although it was statistically insignificant and a correlation with MS could not be detected in this study.


REFERENCES

  1. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.

  2. Neuschwander-Tetri B, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-19.

  3. Jansen PLM. Non-alcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2004; 16: 1079-85.

  4. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, et al. Nonalcoholic fatty liver, steatohepatitis, and metabolic syndrome. Hepatology 2003; 37: 917-23.

  5. Marchesini G, Brizi M, Bianchi G, Bugianesi E, Lenzi M, McCullough AJ, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.

  6. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, Cavallo MG, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005; 90: 1578-82.

  7. Preuss HG. Effects of glucose/insulin perturbations on aging and chronic disorders of aging: the evidence. J Am Coll Nutr 1997; 16: 397-403.

  8. Czaja MJ. Liver injury in the seting of steatosis: crosstalk between adipokine and cytokines. Hepatology 2004; 40: 19-21.

  9. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999; 892: 146-54.

  10. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissue of obese humans. Endocrinol 2004; 145: 2273-82.

  11. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-56.

  12. Medina J, Fernández-Salazar L, García-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004; 27: 2057-66.

  13. Day CP, James OW. Steatohepatitis: A tail of two «Hits»? Gastroenterology 1998; 114: 842-4.

  14. Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 2004; 287: F7-16.

  15. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 2004; 5: 153-65.

  16. Rahmini N, Saulnier R, Nakamura T, Park M, Elliott B. Role of hepatocyte growth factor in breast cancer: a novel mitogenic factor secreted by adipocytes. DNA Cell Biol 1994; 13: 1189-97.

  17. Hiratsuka A, Adachi H, Fujiura Y, Yamagishi SI, Hirai Y, Enomoto M, Satoh A, et al. Strong Association between Serum Hepatocyte Growth Factor (HGF) and Metabolic Syndrome. J Clin Endocrinol Metab 2005; 90: 2927-31.

  18. Brunt EM, JanneyCJ, Di BisceglieAM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999; 94: 2467-74.

  19. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-39.

  20. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, De Iasio R, Gentilcore E, et al. Plasma adiponectin in nonalcoholic fatty liver is related to heptic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90: 3498-504.

  21. Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997; 276: 60-6.

  22. Zimmermann A. Regulation of liver regeneration. Nephrol Dial Transplant 2004; 19 (Suppl 4): iv 6-10.

  23. Ohnishi T, Daikuhara T. Hepatocyte growth factor/scatter factor in development, inflammation and carcinogenesis: its expression and role in oral tissues. Arch Oral Bio 2003; 48: 797-804.

  24. Birchmeier C, Birchmeier W, Gherardi E, Woude GFV. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-25.

  25. Stuart KA, Riordan SM, Lidder S, Crostella L, Williams R, Skouteris GG. Hepatocyte growth factor/scatter factor-induced intracellular signaling. Int J Exp Path 2000; 81: 17-30.

  26. Neo S, Kansaku N, Furuichi M, Watanabe M, Hisamatsu S, Ohno K, Hisasue M, et al. Molecular cloning of the canine c-Met/HGF receptor and its expression in normal and regenerated liver. J Vet Med Sci 2005; 67: 525-9.

  27. He Y, Zhou J, Dou KF, Chen Y, Yan QG, Li HM. Autocrine expression of hepatocyte growth factor and its cytoprotective effect on hepatocyte poisoning. Wold J Gastroenterol 2004; 10: 2827-30.

  28. Kaido T, Imamura M. Hepatocyte growth factor: clinical implications in hepatobiliary pancreatic surgery. J Hepatobiliary Pancreat Surg 2001; 8: 65-75.

  29. Lotersztajn S, Julen B, Teixeriara-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005; 45: 605-28.

  30. Rehman J, Considine RV, Bovenkerk JE, Li J, Slavens CA, Jones RM, March KL. Obesity is associated with increased levels of circulating hepatocyte growth factor. J Am Coll Cardiol 2003; 41: 1408-13.

  31. Tamama K, Sumino H, Ichikawa S, Kanda T, Kotajima N, Fukumura Y, Kurabayashi M, et al. Hormon replacement therapy causes a decrease in hepatocyte growth factor in hypertensive women. J Hypertens 2003; 21: 1151-6.




2020     |     www.medigraphic.com